A daily pill for ulcerative colitis, an autoimmune disease, beat placebo in a trial
☕ Includes a question for the family ↓
Autoimmune diseasesPart of a story we are following · 1 article · See every update
If you live with ulcerative colitis, here is news worth a smile with your coffee: a pill you take once a day worked in a major trial. Today’s best treatments that block this immune signal come as infusions or injections. This pill does the same job by mouth.
Ulcerative colitis is an autoimmune disease. Your immune system inflames the lining of the large intestine, which causes diarrhea, bleeding and urgency. In the trial, the pill, called icotrokinra, helped far more people improve than a placebo did.
How the study worked
Researchers followed 252 adults with moderately to severely active ulcerative colitis. By chance, each person took icotrokinra once a day at 400 mg, 200 mg or 100 mg, or took a placebo. Neither the patients nor the doctors knew who got what. The main goal was to see how many people improved by week 12, and the team kept tracking safety through week 28. It was a mid-stage trial paid for by Johnson & Johnson, so larger trials come next. The results were published on October 15, 2026 in the New England Journal of Medicine.
What they found
Every dose beat placebo on the main goal, a clinical response at week 12. That means the disease clearly got better. It happened in 63% of people taking 400 mg, 58% taking 200 mg and 55% taking 100 mg. Among people on placebo, it happened in 27%.
| 400 mg | 63% |
|---|---|
| 200 mg | 58% |
| 100 mg | 55% |
| Placebo | 27% |
The top dose also did better on the tougher goals, compared with placebo:
- Clinical remission, meaning the disease calmed down: 30% vs. 11%.
- Remission of symptoms: 46% vs. 19%.
- Healing seen when doctors looked inside the colon with a scope: 37% vs. 14%.
Safety looked reassuring. Through week 28, side effects of any kind showed up in 60% of the 400 mg group and 62% of the placebo group. Serious side effects were reported in 2% of the 400 mg group, 5% of the 200 mg group, 0% of the 100 mg group and 10% of the placebo group.
Why a pill matters
Many people with ulcerative colitis would simply rather take a pill. A daily pill skips the trips to an infusion center and the needles. It can also be easier to start, stop or adjust. The pill works by blocking the receptor for interleukin-23, a signal your immune system uses to drive inflammation in the gut. That is the same signal the injected antibody drugs target, so this is a proven approach in a new form.
The pill isn’t available at the pharmacy yet. But a clear win at three different doses is a strong sign for the next round of testing.
What you can do today
If you have ulcerative colitis, start a simple symptom log this week. Each day, jot down how many bowel movements you have, whether you see blood, and how urgent it feels. Bring those notes to your next gastroenterology visit. They help your doctor see how well your current treatment is working, and they make it easy to ask whether a clinical trial near you might be a fit. Keep taking your current medicines as prescribed while you do.
Talk about it at home
Sometimes the body’s defense system gets confused and attacks the body itself, and that is what happens in the gut with ulcerative colitis. Scientists found a pill that quiets one of the signals that makes the defense system angry. In the trial, some volunteers got the real pill and others got a pill with nothing in it, and nobody knew who got which.
Question for the table
Why do you think the scientists gave some people a pill with nothing in it, and kept everyone in the dark about who got which?
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Questions and answers
- What is icotrokinra?
- It is a pill taken once a day that blocks the receptor for interleukin-23, an immune signal that drives inflammation in the gut.
- How well did it work?
- At week 12, 63% of people taking 400 mg improved clinically, compared with 27% of people on placebo. The 200 mg and 100 mg doses also beat placebo.
- Was it safe in the trial?
- Side effects of any kind were similar across groups, from 60% to 66%. Serious side effects were 2% at 400 mg and 10% on placebo.
- Can I get this pill now?
- Not yet. It was a mid-stage trial, and larger trials are the next step.